On day 14 post-infection, we reported the effect of ACE2 on the levels of anti-SARS-CoV-2 IgG and IgM antibodies, finding that they were higher in the more severe cases compared to the moderate COVID-19 group. The gene discussed is ACE2; the disease is COVID-19.